Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 25, 2023

Effectiveness of Cilta-Cel vs Real-World Clinical Practice Therapies in Patients With Triple Class–Exposed Relapsed/Refractory Multiple Myeloma



Additional Info

Disclosure statements are available on the authors' profiles:

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Haematologica 2022 Dec 22;[EPub Ahead of Print], MV Mateos, K Weisel, T Martin, JG Berdeja, A Jakubowiak, AK Stewart, S Jagannath, Y Lin, J Diels, F Ghilotti, P Thilakarathne, NJ Perualila, J Cabrieto, B Haefliger, N Erler-Yates, C Hague, CC Jackson, JM Schecter, V Strulev, T Nesheiwat, L Pacaud, H Einsele, P Moreau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading